Challenges in the diagnosis of Parkinson's disease
Parkinson's disease is the second most common neurodegenerative disease and its
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …
[HTML][HTML] Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies
Biomarkers of neurodegeneration and neuronal injury have the potential to improve
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
diagnostic accuracy, disease monitoring, prognosis, and measure treatment efficacy …
Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration
F Gonzalez-Ortiz, M Turton, PR Kac, D Smirnov… - Brain, 2023 - academic.oup.com
Blood-based biomarkers for amyloid beta and phosphorylated tau show good diagnostic
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
accuracies and agreements with their corresponding CSF and neuroimaging biomarkers in …
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective …
Background CSF and PET biomarkers of amyloid β and tau accurately detect Alzheimer's
disease pathology, but the invasiveness, high cost, and poor availability of these detection …
disease pathology, but the invasiveness, high cost, and poor availability of these detection …
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD),
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P …
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease
J Simrén, A Leuzy, TK Karikari, A Hye… - Alzheimer's & …, 2021 - Wiley Online Library
Introduction This study investigated the diagnostic and disease‐monitoring potential of
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …
plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) …
[HTML][HTML] Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of …
The neuropathological confirmation of amyloid-β (Aβ) plaques and tau neurofibrillary
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …
tangles (NFT) remains the gold standard for a definitive diagnosis of Alzheimer's disease …
Neurofilaments as biomarkers in neurological disorders
M Khalil, CE Teunissen, M Otto, F Piehl… - Nature Reviews …, 2018 - nature.com
Neuroaxonal damage is the pathological substrate of permanent disability in various
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …
neurological disorders. Reliable quantification and longitudinal follow-up of such damage …
Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative
Whilst cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers for
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease …
amyloid-β (Aβ) and tau pathologies are accurate for the diagnosis of Alzheimer's disease …
CSF and blood biomarkers for Parkinson's disease
L Parnetti, L Gaetani, P Eusebi, S Paciotti… - The Lancet …, 2019 - thelancet.com
In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers
are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical …
are urgently needed. The diagnosis of Parkinson's disease mostly relies on clinical …